Cho Yong-Hee
Data Convergence Drug Research Center, Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Korea.
Curr Issues Mol Biol. 2022 Oct 31;44(11):5352-5362. doi: 10.3390/cimb44110362.
Intensive efforts to develop anti-cancer agents have been made for over 60 years. However, cancer is still considered a lethal disease. To study the best anti-cancer agents for improving the survival rates of cancer patients, many researchers have focused on establishing advanced experimental applications reflecting on the biomimetics of cancer patients involving the heterogeneity of cancer cells. The heterogeneity of cancer cells, which are derived from various clones and affected by different environments, presents different genetic backgrounds and molecular characteristics attributed to the differential responses to cancer therapies, and these are responsible for the resistance to cancer therapies, as well as for recurrence following cancer treatments. Therefore, the development of advanced applications for the cancer patient is expected to help the development of more effective anti-cancer agents. The present review evaluates recently developed cancer models encompassing the heterogeneity of cancer cells, which present similar morphological architecture, genetic backgrounds, and molecular characteristics to corresponding patient tumor tissues.
60多年来,人们一直在大力研发抗癌药物。然而,癌症仍然被认为是一种致命疾病。为了研究提高癌症患者生存率的最佳抗癌药物,许多研究人员专注于建立先进的实验应用,以反映涉及癌细胞异质性的癌症患者的生物模拟。癌细胞的异质性源于各种克隆并受不同环境影响,呈现出不同的遗传背景和分子特征,这归因于对癌症治疗的不同反应,并且这些导致了对癌症治疗的抗性以及癌症治疗后的复发。因此,开发针对癌症患者的先进应用有望有助于开发更有效的抗癌药物。本综述评估了最近开发的包含癌细胞异质性的癌症模型,这些模型与相应患者肿瘤组织具有相似的形态结构、遗传背景和分子特征。